ACVR2A Antibody

What is ACVR2A and why are antibodies against it important for research?

ACVR2A (activin A receptor type 2A) is a transmembrane serine/threonine kinase receptor that functions in the activin and myostatin signaling pathway. It plays crucial roles in cell differentiation, among other biological processes . The human version has a canonical amino acid length of 513 residues and a molecular weight of approximately 57.8 kilodaltons, with two identified isoforms .

Antibodies against ACVR2A are essential research tools that enable detection and measurement of this receptor in biological samples, facilitating studies on TGF-beta family signaling, developmental biology, and disease mechanisms related to dysregulated activin signaling .

What are the most common applications for ACVR2A antibodies?

ACVR2A antibodies are primarily used for:

• Western Blot (WB): Most commonly used for protein detection and quantification

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative measurement

• Immunohistochemistry (IHC): To visualize tissue distribution and localization

• Flow Cytometry: For cell-based detection and quantification

• Immunofluorescence (IF): For subcellular localization studies

• Immunocytochemistry (ICC): For detection in cultured cells

The selection of application should be guided by experimental objectives and available antibody validation data.

How should I validate the specificity of an ACVR2A antibody for my research?

Validation of ACVR2A antibody specificity should include multiple approaches:

• Positive and negative controls: Use tissues or cell lines known to express or lack ACVR2A (positive samples include SW480, mouse kidney, rat testis, and rat ovary)

• Multiple detection methods: Compare results across different applications (WB, IHC, IF)

• Blocking peptide experiment: Pre-incubate the antibody with the immunizing peptide to confirm signal specificity

• Knockout/knockdown verification: Test the antibody in ACVR2A knockout or knockdown samples

• Cross-reactivity assessment: Test against closely related proteins (e.g., ACVR2B) to ensure specificity

• Molecular weight verification: Confirm detection at the expected molecular weight (~58 kDa)

What are the optimal conditions for Western blot detection of ACVR2A?

For optimal Western blot detection of ACVR2A:

• Sample preparation: Use RIPA or NP-40 buffer with protease inhibitors

• Gel percentage: 7.5-10% SDS-PAGE gels are recommended for better resolution of the 58 kDa protein

• Transfer conditions: 150 mA for 50-90 minutes to a nitrocellulose membrane

• Blocking: 5% non-fat milk in TBS for 1.5 hours at room temperature

• Primary antibody: Dilution ranges from 1:500-1:2000, incubate overnight at 4°C

• Secondary antibody: Anti-rabbit or anti-mouse HRP-conjugated antibody at 1:5000 dilution

• Detection: Enhanced chemiluminescence (ECL) systems provide adequate sensitivity

• Expected band size: Primary band at ~58 kDa, though some antibodies may detect bands at ~75 kDa due to post-translational modifications

What are the recommended protocols for immunohistochemical detection of ACVR2A?

For successful immunohistochemical detection of ACVR2A:

• Fixation: 4% paraformaldehyde or formalin-fixed paraffin-embedded (FFPE) tissues

• Antigen retrieval: Heat-mediated antigen retrieval in EDTA buffer (pH 8.0) is recommended for most antibodies

• Blocking: 10% goat serum to minimize background staining

• Primary antibody: Optimal concentration ranges from 1-2 μg/ml, incubate overnight at 4°C

• Detection system: Biotin-streptavidin systems with DAB as chromogen work well for colorimetric detection

• Counterstaining: Hematoxylin provides good nuclear contrast

• Expected staining pattern: Primarily membrane localization with potential cytoplasmic staining in various tissue types, including skin, intestine, and bone cells

Why might my Western blot for ACVR2A show multiple bands or unexpected molecular weights?

Multiple bands or unexpected molecular weights in ACVR2A Western blots could result from:

• Post-translational modifications: Glycosylation, phosphorylation, or ubiquitination can alter migration patterns, potentially resulting in bands at ~75 kDa rather than the expected 58 kDa

• Isoforms: ACVR2A has at least two identified isoforms which may appear as distinct bands

• Proteolytic degradation: Inadequate sample handling or insufficient protease inhibitors can lead to degradation fragments

• Cross-reactivity: Some antibodies may cross-react with the structurally similar ACVR2B receptor

• Antibody specificity issues: Different epitope regions may detect different forms of the protein

• Sample preparation conditions: Reducing vs. non-reducing conditions can affect band patterns for transmembrane proteins

To address these issues, try using fresh samples with complete protease inhibitor cocktails, optimize sample preparation conditions, and compare results with multiple antibodies targeting different epitopes of ACVR2A.

How can I optimize immunofluorescence staining for ACVR2A in cultured cells?

To optimize immunofluorescence staining for ACVR2A in cultured cells:

• Fixation optimization: Compare 4% paraformaldehyde (10-15 minutes) with methanol fixation (-20°C, 10 minutes) to determine which better preserves the epitope

• Permeabilization: Use 0.1-0.3% Triton X-100 in PBS for 10 minutes for adequate membrane permeabilization

• Blocking: Employ 5-10% normal serum (from the species of secondary antibody) with 1% BSA for 1 hour

• Antibody concentration titration: Test a range of primary antibody concentrations (0.5-5 μg/ml)

• Incubation conditions: Compare room temperature (1-2 hours) vs. 4°C overnight incubation

• Signal amplification: Consider using tyramide signal amplification for low-abundance targets

• Counterstaining: Use DAPI for nuclear visualization and phalloidin for F-actin to provide cellular context

• Controls: Include a secondary-only control and, if possible, ACVR2A-knockout or knockdown samples

What are the common issues when using ACVR2A antibodies in flow cytometry and how can they be resolved?

Common issues and solutions for ACVR2A flow cytometry:

For optimal flow cytometry results, researchers should use ACVR2A-expressing cells (like HEPA1-6 or RH35) as positive controls and include appropriate isotype controls (rabbit IgG at matching concentrations) .

How can ACVR2A antibodies be used to study receptor complex formation with type I receptors and ligands?

To study ACVR2A receptor complex formation:

• Co-immunoprecipitation (Co-IP): Use ACVR2A antibodies to pull down receptor complexes, followed by Western blot analysis for type I receptors (like ALK4/ACVR1B) or associated SMADs

• Proximity ligation assay (PLA): Detect protein-protein interactions within 40 nm using primary antibodies against ACVR2A and potential binding partners

• Immunofluorescence co-localization: Dual staining with antibodies against ACVR2A and type I receptors to visualize co-localization after ligand stimulation

• FRET/BRET analysis: Using fluorescently tagged antibodies or labeled receptors to detect interactions in live cells

• Surface plasmon resonance (SPR): Use purified ACVR2A-Fc fusion proteins with antibodies to study binding kinetics of different ligands (activin A, activin B, BMP7, etc.)

These approaches can reveal how ACVR2A interacts with different ligands and type I receptors to form signaling complexes that activate downstream SMAD2/3 pathways .

How do ACVR2A antibodies compare to soluble ACVR2A-Fc fusion proteins as research tools for manipulating activin signaling?

ACVR2A antibodies and soluble ACVR2A-Fc fusion proteins offer distinct advantages for manipulating activin signaling:

Research has shown that ACVR2A-Fc treatment increases bone volume and cortical thickness while simultaneously increasing muscle mass, demonstrating its effectiveness as a tool for studying the physiological roles of activin signaling .

What are the considerations for using ACVR2A antibodies in investigating bone and muscle development research?

When using ACVR2A antibodies for bone and muscle development research:

• Tissue-specific expression: ACVR2A is expressed in osteoblasts, osteocytes, and muscle cells, requiring careful validation of antibody performance in these specific tissues

• Developmental timing: Expression of ACVR2A increases during osteoblast differentiation, necessitating time-course studies with appropriate antibody selection

• Functional blockade assessment: When using blocking antibodies, confirm inhibition of SMAD2/3 phosphorylation as a readout for pathway inhibition

• Cross-reactivity with ACVR2B: While ACVR2A appears to be the predominant receptor in osteoblasts, carefully assess antibody cross-reactivity with ACVR2B

• Histological applications: For bone tissues, optimize decalcification protocols that preserve epitope recognition by ACVR2A antibodies

• Genetic model comparisons: Compare antibody results with ACVR2A conditional knockout models to validate findings

Research has demonstrated that ACVR2A functions directly in osteoblasts as a negative regulator of bone mass, with ACVR2A-deficient mice showing increased trabecular bone volume and enhanced osteoblast differentiation .

What methodological approaches enable the development of antibodies that can distinguish between closely related ACVR2A and ACVR2B receptors?

Developing antibodies that can distinguish between ACVR2A and ACVR2B requires:

• Epitope selection: Identify unique sequences with low homology between ACVR2A and ACVR2B, particularly in the extracellular domain or C-terminal regions

• Recombinant protein immunization: Use highly purified receptor-specific domains as immunogens

• Subtraction strategies: Pre-absorb antibody preparations with the related receptor to remove cross-reactive antibodies

• Validation in knockout models: Test antibodies in ACVR2A and ACVR2B knockout tissues to confirm specificity

• Computational antibody design: New approaches like those described in the biorxiv paper can generate antibodies with high specificity for distinguishing closely related protein subtypes

• Cross-reactivity testing: Comprehensive testing against both receptors under identical conditions

Recent research has demonstrated that computational antibody design methods can achieve molecular specificity capable of distinguishing closely related protein subtypes or mutants, which could be applied to developing highly specific antibodies for ACVR2A versus ACVR2B .

How are ACVR2A antibodies being utilized in therapeutic target validation research?

ACVR2A antibodies are increasingly important in therapeutic target validation through:

• Blocking antibody studies: Evaluating the consequences of ACVR2A inhibition in disease models to predict therapeutic outcomes

• Target expression profiling: Characterizing ACVR2A expression across tissues and disease states to identify potential treatment indications

• Mechanism of action studies: Determining how ACVR2A signaling contributes to pathological processes

• Comparison with small molecule inhibitors: Benchmarking antibody-based inhibition against small molecule approaches targeting the same pathway

• Biomarker development: Using antibodies to quantify ACVR2A expression or activation as potential biomarkers of disease progression or treatment response

Researchers have utilized both ACVR2A antibodies and ACVR2A-Fc fusion proteins to demonstrate that inhibiting activin receptor signaling can increase bone mass and muscle development, highlighting its potential as a therapeutic target for musculoskeletal disorders .

What experimental design is optimal for using ACVR2A antibodies to distinguish between activin and myostatin signaling pathways?

To distinguish between activin and myostatin signaling pathways using ACVR2A antibodies:

• Comparative stimulation experiments:

  • Treat cells with specific ligands (activin A vs. myostatin/GDF8)

  • Use ACVR2A antibodies to detect receptor recruitment/activation

  • Compare with ACVR2B antibodies (myostatin preferentially signals through ACVR2B)

• Co-immunoprecipitation analysis:

  • Immunoprecipitate with ACVR2A antibodies after ligand stimulation

  • Identify differential co-precipitation of type I receptors (ALK4/5 for activin vs. ALK4/5 for myostatin)

  • Compare ligand binding using antibodies against activin and myostatin

• Phospho-SMAD analysis:

  • Block ACVR2A with specific antibodies

  • Quantify differential effects on SMAD2/3 phosphorylation after activin vs. myostatin stimulation

  • Include controls with ACVR2B blockade

• Receptor competition assays:

  • Use labeled ligands and ACVR2A antibodies to block binding

  • Compare IC50 values for displacement of activin vs. myostatin

  • Include soluble receptor controls (ACVR2A-Fc vs. ACVR2B-Fc)

• Tissue-specific analyses:

  • Compare ACVR2A antibody staining patterns in muscle vs. bone tissues

  • Correlate with known activin vs. myostatin expression patterns

These approaches help delineate the distinct but overlapping roles of these related signaling pathways in different biological contexts.